Innate control of the inflammatory process during fungal infections

真菌感染期间炎症过程的先天控制

基本信息

  • 批准号:
    10641775
  • 负责人:
  • 金额:
    $ 51.38万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-03-01 至 2026-05-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY The dialogue between innate and adaptive branches of the immune system is a central paradigm of modern immunology and is vital for protection against infections as well as for the pathogenesis of autoimmune, allergic and inflammatory diseases. According to the current model, innate immune sentinels dispersed throughout peripheral tissues sense, via their pattern recognition receptors (PRRs), the presence of microbial clues or endogenous moieties released during an infection, are activated and migrate to the draining lymph node (dLN). This process enables a transfer of “information” from peripheral tissue to the dLN, where the antigen-dependent adaptive immune response against the pathogen is initiated. The dLN also hosts an initial antigen-independent, innate immune response governed by migrating phagocytes that enables expansion of the LN and establishes a pro-inflammatory milieu. These events are required for the development and polarization of the adaptive immune response. Here, we focused our attention on the capacity of ligands derived from the cell wall of Candida (C.) albicans to dictate the LN innate response. Our working hypothesis is that the size and solubility of stimuli that activate the PRRs affect not only the LN innate response itself, but also the final outcome of the immune response. Also, that the LN innate response initiated by soluble fungal ligands can be harnessed to develop a potent and protective adaptive immune response to prevent life-threatening systemic fungal infections. Our preliminary data demonstrate that the physical form of fungal ligands dictates the location where the initial immune response takes place, and thereby determines the activation of adaptive immunity. In particular, we have found that small soluble fungal ligands that are immunosilent in the periphery and do not cause an inflammation in the tissue, become potent immunogens once they reach the dLN. Also, that the LN innate response initiated by these ligands completely bypasses the need of phagocyte migration from the periphery into the dLN and, instead, requires a unique gene signature that is characterized by the production of interferons and that is driven by the activation of the noncanonical NFkB transcription factor RelB in subcapsular sinus macrophages. Notably, Dectins are required for this process but CARD9, the key signaling adaptor downstream of Dectins, is largely dispensable. Plus, the initial innate response to the dLN instructs a potent type 1 adaptive immunity and allows the production of antibodies directed against the most external layer of the fungal cell wall. Fungal diseases are a global health problem and Candida species are the most common cause of invasive fungal infections. We propose to unravel how physical properties of the PAMPs can be harnessed as a therapeutic intervention against systemic fungal infections that are a major medical problem in the US. We anticipate that identifying new features of the immune response that is anatomically restricted to the LN will help with the design of an improved vaccine against poorly controlled pathogens.
项目总结

项目成果

期刊论文数量(12)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Microbiome studies in the medical sciences and the need for closer multidisciplinary interplay.
医学中的微生物组研究以及更密切的多学科相互作用的需要。
  • DOI:
    10.1126/scisignal.aba9911
  • 发表时间:
    2020
  • 期刊:
  • 影响因子:
    7.3
  • 作者:
    Mancini,Nicasio;Peri,Francesco;Rescigno,Maria;Zanoni,Ivan
  • 通讯作者:
    Zanoni,Ivan
μMAPPS: a novel phasor approach to second harmonic analysis for in vitro-in vivo investigation of collagen microstructure.
  • DOI:
    10.1038/s41598-017-17726-y
  • 发表时间:
    2017-12-12
  • 期刊:
  • 影响因子:
    4.6
  • 作者:
    Radaelli F;D'Alfonso L;Collini M;Mingozzi F;Marongiu L;Granucci F;Zanoni I;Chirico G;Sironi L
  • 通讯作者:
    Sironi L
Immunobiology of Carbohydrates: Implications for Novel Vaccine and Adjuvant Design Against Infectious Diseases.
Editorial: Interferon-λs: New Regulators of Inflammatory Processes.
社论:干扰素:炎症过程的新调节器。
  • DOI:
    10.3389/fimmu.2019.02117
  • 发表时间:
    2019
  • 期刊:
  • 影响因子:
    7.3
  • 作者:
    Zanoni,Ivan;Odendall,Charlotte
  • 通讯作者:
    Odendall,Charlotte
Host-derived oxidized phospholipids initiate effector-triggered immunity fostering lethality upon microbial encounter.
宿主来源的氧化磷脂启动效应子触发的免疫,在微生物遭遇时产生致命性。
  • DOI:
    10.1101/2023.11.21.568047
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Gioia,MarcoDi;Poli,Valentina;Tan,PiaoJ;Spreafico,Roberto;Chu,Anne;Cuenca,AlexG;Gordts,PhilipLsm;Pandolfi,Laura;Meloni,Federica;Witztum,JosephL;Chou,Janet;Springstead,JamesR;Zanoni,Ivan
  • 通讯作者:
    Zanoni,Ivan
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ivan Zanoni其他文献

Ivan Zanoni的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ivan Zanoni', 18)}}的其他基金

Macrophage immunometabolism controls septic shock
巨噬细胞免疫代谢控制感染性休克
  • 批准号:
    10658162
  • 财政年份:
    2023
  • 资助金额:
    $ 51.38万
  • 项目类别:
Development of a novel adjuvant strategy enabled by modulation of the physical properties of fungal mannans
通过调节真菌甘露聚糖的物理特性开发新型佐剂策略
  • 批准号:
    10338399
  • 财政年份:
    2021
  • 资助金额:
    $ 51.38万
  • 项目类别:
Development of a novel adjuvant strategy enabled by modulation of the physical properties of fungal mannans
通过调节真菌甘露聚糖的物理特性开发新型佐剂策略
  • 批准号:
    10490881
  • 财政年份:
    2021
  • 资助金额:
    $ 51.38万
  • 项目类别:
Development of a novel adjuvant strategy enabled by modulation of the physical properties of fungal mannans
通过调节真菌甘露聚糖的物理特性开发新型佐剂策略
  • 批准号:
    10687182
  • 财政年份:
    2021
  • 资助金额:
    $ 51.38万
  • 项目类别:
Innate control of the inflammatory process during fungal infections
真菌感染期间炎症过程的先天控制
  • 批准号:
    10434924
  • 财政年份:
    2016
  • 资助金额:
    $ 51.38万
  • 项目类别:
Innate control of the inflammatory process during fungal infections
真菌感染期间炎症过程的先天控制
  • 批准号:
    10293993
  • 财政年份:
    2016
  • 资助金额:
    $ 51.38万
  • 项目类别:
Innate control of the inflammatory process during fungal infections
真菌感染期间炎症过程的先天控制
  • 批准号:
    9122779
  • 财政年份:
    2016
  • 资助金额:
    $ 51.38万
  • 项目类别:
Innate control of the inflammatory process during fungal infections
真菌感染期间炎症过程的先天控制
  • 批准号:
    9232989
  • 财政年份:
    2016
  • 资助金额:
    $ 51.38万
  • 项目类别:

相似海外基金

Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
  • 批准号:
    23K08213
  • 财政年份:
    2023
  • 资助金额:
    $ 51.38万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
  • 批准号:
    2881726
  • 财政年份:
    2023
  • 资助金额:
    $ 51.38万
  • 项目类别:
    Studentship
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
  • 批准号:
    10735090
  • 财政年份:
    2023
  • 资助金额:
    $ 51.38万
  • 项目类别:
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
  • 批准号:
    10722146
  • 财政年份:
    2023
  • 资助金额:
    $ 51.38万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 51.38万
  • 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
  • 批准号:
    10935776
  • 财政年份:
    2023
  • 资助金额:
    $ 51.38万
  • 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
  • 批准号:
    10935796
  • 财政年份:
    2023
  • 资助金额:
    $ 51.38万
  • 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
  • 批准号:
    10935775
  • 财政年份:
    2023
  • 资助金额:
    $ 51.38万
  • 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
  • 批准号:
    10649041
  • 财政年份:
    2023
  • 资助金额:
    $ 51.38万
  • 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
  • 批准号:
    10735964
  • 财政年份:
    2023
  • 资助金额:
    $ 51.38万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了